Common Gastrointestinal Stromal Tumor Medications

The venetoclax regimen improved CR/CRi rates for patients with acute myeloid leukemia and myelodysplastic syndromes.

Andrew M. Evens, DO, MBA, MSc, discusses the importance of meeting the emotional and physical needs of cancer survivors to help them lead fruitful lives.

Minimal tumor lysis syndrome was observed with venetoclax combined with hypomethylating agents in patients with myelodysplastic syndrome.

A nurse practitioner discussed risk factors, diagnostic challenges, and treatment planning in patients with pancreatic cancers.

Navtemadlin shows influence in myelofibrosis hallmarks such as CD34-positive cell proliferation and pro-inflammatory cytokines in the phase 3 BOREAS trial.

For patients with MDS who are relapsed/refractory to erythropoietin stimulating agents, low-dose deferasirox demonstrated promising efficacy and tolerability outcomes.